Myriad Genetics (NASDAQ:MYGN) Releases FY 2025 Earnings Guidance

Myriad Genetics (NASDAQ:MYGN) issued an update on its FY 2025 earnings guidance on Monday morning. The company provided earnings per share (EPS) guidance of -0.020-0.02 for the period, compared to the consensus estimate of -0.160. The company issued revenue guidance of $818.0 million-$828.0 million, compared to the consensus revenue estimate of $822.2 million.

Myriad Genetics Trading Up 1.7%

MYGN traded up $0.14 on Monday, hitting $8.18. 1,866,863 shares of the company’s stock were exchanged, compared to its average volume of 1,626,906. The firm has a market cap of $761.11 million, a PE ratio of -1.91 and a beta of 1.97. Myriad Genetics has a twelve month low of $3.76 and a twelve month high of $19.60. The stock has a fifty day moving average of $7.44 and a two-hundred day moving average of $6.04.

Myriad Genetics (NASDAQ:MYGN) last posted its earnings results on Tuesday, January 16th. The company reported ($0.19) EPS for the quarter. Myriad Genetics had a negative return on equity of 5.17% and a negative net margin of 47.45%.The firm had revenue of $156.40 million during the quarter. Myriad Genetics has set its FY23 guidance at ($0.33)-($0.28) EPS. On average, analysts predict that Myriad Genetics will post -0.3 EPS for the current year.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Myriad Genetics in a research report on Tuesday, October 14th. Four analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $12.45.

Institutional Investors Weigh In On Myriad Genetics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Baird Financial Group Inc. bought a new stake in Myriad Genetics during the first quarter worth approximately $105,000. Royal Bank of Canada boosted its holdings in Myriad Genetics by 82.4% during the first quarter. Royal Bank of Canada now owns 33,326 shares of the company’s stock worth $296,000 after buying an additional 15,057 shares in the last quarter. AQR Capital Management LLC boosted its holdings in Myriad Genetics by 278.9% during the first quarter. AQR Capital Management LLC now owns 433,392 shares of the company’s stock worth $3,844,000 after buying an additional 319,007 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in Myriad Genetics by 4.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,256 shares of the company’s stock worth $2,654,000 after buying an additional 14,027 shares in the last quarter. Finally, Jane Street Group LLC boosted its holdings in Myriad Genetics by 1,076.9% during the first quarter. Jane Street Group LLC now owns 213,826 shares of the company’s stock worth $1,897,000 after buying an additional 195,658 shares in the last quarter. 99.02% of the stock is owned by institutional investors and hedge funds.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.